138 related articles for article (PubMed ID: 38539054)
1. Value of autotaxin for hepatocellular carcinoma risk assessment in chronic hepatitis B patients treated with nucleos(t)ide analogs.
Hiyama Y; Fujino H; Namba M; Fujii Y; Uchikawa S; Ono A; Nakahara T; Murakami E; Kawaoka T; Miki D; Tsuge M; Oka S
Hepatol Res; 2024 Mar; ():. PubMed ID: 38539054
[TBL] [Abstract][Full Text] [Related]
2. Association of serum autotaxin levels with liver fibrosis in patients pretreatment and posttreatment with chronic hepatitis C.
Takemura K; Takizawa E; Tamori A; Nakamae M; Kubota H; Uchida-Kobayashi S; Enomoto M; Kawada N; Hino M
J Gastroenterol Hepatol; 2021 Jan; 36(1):217-224. PubMed ID: 32453907
[TBL] [Abstract][Full Text] [Related]
3. Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C.
Takemura K; Takizawa E; Tamori A; Nakamae M; Kubota H; Uchida-Kobayashi S; Enomoto M; Kawada N; Hino M
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630450
[TBL] [Abstract][Full Text] [Related]
4. Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.
Farquhar MJ; Humphreys IS; Rudge SA; Wilson GK; Bhattacharya B; Ciaccia M; Hu K; Zhang Q; Mailly L; Reynolds GM; Ashcroft M; Balfe P; Baumert TF; Roessler S; Wakelam MJO; McKeating JA
J Hepatol; 2017 May; 66(5):919-929. PubMed ID: 28126468
[TBL] [Abstract][Full Text] [Related]
5. High percentage atypical hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs.
Lin CC; Bair MJ; Liu CY; Lin ZY; Chen CJ; Chen MJ; Chu CH; Wang HY; Shih SC; Wang TE
Medicine (Baltimore); 2019 Jan; 98(1):e13818. PubMed ID: 30608393
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.
Kaneko S; Kurosaki M; Mashiba T; Marusawa H; Kondo M; Kojima Y; Uchida Y; Fujii H; Akahane T; Yagisawa H; Kusakabe A; Kobashi H; Abe T; Yoshida H; Ogawa C; Furuta K; Tamaki N; Tsuji K; Matsushita T; Izumi N;
J Med Virol; 2023 Jan; 95(1):e28210. PubMed ID: 36222204
[TBL] [Abstract][Full Text] [Related]
7. Serum autotaxin is a useful liver fibrosis marker in patients with chronic hepatitis B virus infection.
Joshita S; Ichikawa Y; Umemura T; Usami Y; Sugiura A; Shibata S; Yamazaki T; Fujimori N; Komatsu M; Matsumoto A; Igarashi K; Ota M; Tanaka E
Hepatol Res; 2018 Mar; 48(4):275-285. PubMed ID: 29114991
[TBL] [Abstract][Full Text] [Related]
8. The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients.
Hiramatsu N; Yamada R; Takehara T
J Gastroenterol Hepatol; 2016 Mar; 31(3):546-52. PubMed ID: 26574149
[TBL] [Abstract][Full Text] [Related]
9. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk.
Ren P; Cao Z; Mo R; Liu Y; Chen L; Li Z; Zhou T; Lu J; Liu Y; Guo Q; Chen R; Zhou H; Xiang X; Cai W; Wang H; Bao S; Xu Y; Gui H; Xie Q
Expert Opin Biol Ther; 2018 Oct; 18(10):1085-1094. PubMed ID: 30182763
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study.
Yang DH; Wang WP; Zhang Q; Pan HY; Huang YC; Zhang JJ
World J Gastroenterol; 2021 May; 27(17):2025-2038. PubMed ID: 34007137
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B.
Mao QG; Liang HQ; Yin YL; Tang JM; Yang JE; Wu CC; Chen Y; Zhang MY; Liu YY; Zheng XT; Zhuang LY; Chen SD
Clin Res Hepatol Gastroenterol; 2022 Jan; 46(1):101758. PubMed ID: 34303003
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of the Fibrosis-4 index and alanine aminotransferase at 1 year of nucleos(t)ide analog treatment for prediction of hepatocellular carcinoma in chronic hepatitis B patients.
Inoue J; Akahane T; Kobayashi T; Kimura O; Sato K; Ninomiya M; Iwata T; Takai S; Kisara N; Sato T; Nagasaki F; Miura M; Nakamura T; Umetsu T; Sano A; Tsuruoka M; Onuki M; Sawahashi S; Niitsuma H; Masamune A;
Hepatol Res; 2024 Feb; 54(2):131-141. PubMed ID: 37621201
[TBL] [Abstract][Full Text] [Related]
13. Effect of Nucleos(t)ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma.
Jian ZW; Wu XW; Chen ZX; Wang JC; Peng JY; Lao XM
Dig Dis Sci; 2019 Aug; 64(8):2187-2198. PubMed ID: 30815819
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs.
Tsai MC; Chen CH; Hu TH; Lu SN; Lee CM; Wang JH; Hung CH
J Formos Med Assoc; 2017 Jul; 116(7):512-521. PubMed ID: 27720344
[TBL] [Abstract][Full Text] [Related]
15. Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patients.
Wang HM; Hung CH; Lee CM; Lu SN; Wang JH; Yen YH; Kee KM; Chang KC; Tseng PL; Hu TH; Chen CH
J Gastroenterol Hepatol; 2016 Jul; 31(7):1307-14. PubMed ID: 26758501
[TBL] [Abstract][Full Text] [Related]
16. Autotaxin: An Early Warning Biomarker for Acute-on-chronic Liver Failure.
Nie C; Zhang L; Chen X; Li Y; Ha F; Liu H; Han T
J Clin Transl Hepatol; 2020 Sep; 8(3):240-245. PubMed ID: 33083245
[No Abstract] [Full Text] [Related]
17. Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular carcinoma: A literature review.
Abd El Aziz MA; Sacco R; Facciorusso A
Antivir Chem Chemother; 2020; 28():2040206620921331. PubMed ID: 32418480
[TBL] [Abstract][Full Text] [Related]
18. [Risk factors for the development of liver cancer in patients with hepatitis B-related liver cirrhosis treated with long-term nucleos(t)ide analogues].
Zang WW; Su MH; Ling XZ; Wang RM; Cao BC; Wu YL; Deng DL; Wei HL; Liang XS; Jiang JN
Zhonghua Gan Zang Bing Za Zhi; 2020 Aug; 28(8):679-685. PubMed ID: 32911907
[No Abstract] [Full Text] [Related]
19. Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C.
Yamazaki T; Joshita S; Umemura T; Usami Y; Sugiura A; Fujimori N; Kimura T; Matsumoto A; Igarashi K; Ota M; Tanaka E
PLoS One; 2018; 13(4):e0195632. PubMed ID: 29617443
[TBL] [Abstract][Full Text] [Related]
20. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis.
Okada M; Enomoto M; Kawada N; Nguyen MH
Expert Rev Gastroenterol Hepatol; 2017 Dec; 11(12):1095-1104. PubMed ID: 28752768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]